SEATTLE, Nov. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC) today announced that Frederick W. Telling, Ph.D., has
agreed to join its board of directors. Dr. Telling is currently the Vice
President of Corporate Policy and Strategic Management for Pfizer Inc. His
responsibilities include the management of Pfizer's worldwide policy function
and external representation of the company's interests to strengthen Pfizer's
ability to anticipate and influence regulatory and competitive trends in the
global marketplace. Pfizer is the world's largest research-based, global
healthcare company.
"We are pleased to welcome Dr. Telling with his leadership and background
in pharmaceutical development, regulatory policy, strategic planning and
mergers and acquisitions," said Phillip M. Nudelman, Chairman of the Board of
CTI. "His experience makes him an ideal addition to CTI's board as we move
forward to get XYOTAX(TM) and pixantrone to patients who will benefit the
most."
"Dr. Telling's considerable pharmaceutical company experience and
extensive industry background will be invaluable to CTI as we grow our
commercial operations," said James A. Bianco, M.D., President and CEO of CTI.
"We are honored to have him on board."
Dr. Telling added, "I am delighted to join Cell Therapeutics' Board and
support its mission to bring novel medicines to cancer patients. The
increasingly complex and time-consuming developmental and regulatory
challenges facing all research-based innovative firms are particularly
daunting for smaller biotech firms, and I look forward to adding my experience
to CTI's dedicated leadership going forward."
Since joining Pfizer in 1977, Telling worked with both their
pharmaceutical and diagnostic products divisions, becoming the Director of
Planning in 1981. In 1987 his responsibilities were expanded and he was
promoted to Vice President, Planning, U.S. Pharmaceuticals. Telling was named
Pfizer's Vice President-Corporate Strategic Planning and Policy in 1994 and
elected a corporate officer and Vice President of the company. In 2001,
Telling assumed his current responsibilities as Vice President-Corporate
Policy and Strategic Management.
Telling is a member of the Board of the Biotechnology Industry
Organization (BIO), the California Health Care Institute, the New England
Healthcare Institute and the Committee for Economic Development (Vice
Chairman). He is actively involved in a number of charitable organizations,
including the Boards of the March of Dimes National Foundation, the United
Hospital Fund, ORBIS, the Smithsonian National Air and Space Museum and the
Experimental Aviation Association (EAA). He is also Vice Chairman for the
American Foundation for Pharmaceutical Education and an invited faculty
lecturer at the Harvard University School of Public Health and Cornell
University. He is involved in the work of the Council on Competitiveness, the
Business Roundtable, the National Association of Manufacturers, and the
Institute of Medicine, where he was a contributing author to the IOM's series
on Technology Innovation in Medicine.
Telling received his BA from Hamilton College and his Master's of
Industrial and Labor Relations and Ph.D. in Economics and Public Policy from
Cornell University.
In addition to Telling, CTI's Board of Directors includes Phillip M.
Nudelman, Ph.D., Chairman of the Board, President and Chief Executive of The
Hope Heart Institute and former President and CEO of Group Health Cooperative;
Vartan Gregorian, Ph.D., President of Carnegie Corporation of New York; Mary
O. Mundinger, D.P.H., Dean and Professor, School of Nursing and Associate
Dean, Faculty of Medicine, Columbia University; John H. Bauer, former EVP of
Finance for Nintendo of America, Inc.; James A. Bianco, M.D., President and
CEO of CTI, and Jack W. Singer, M.D., Chief Medical Officer of CTI.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at making cancer
more treatable. For additional information, please visit www.cticseattle.com.
SOURCE Cell Therapeutics, Inc. 11/29/2006
CONTACT: Dan Eramian, +1-206-272-4343, or cell, +1-206-854-1200, or
Susan Callahan, +1-206-272-4472, or fax, +1-206-272-4434, or
media@ctiseattle.com, or www.cticseattle.com/media.htm, or investors, Leah
Grant, +1-206-282-7100, or fax, +1-206-272-4434, or invest@ctiseattle.com, or
www.cticseattle.com/investors.htm, all of Cell Therapeutics, Inc.
Web site: http://www.cticseattle.com
(CTIC)
7870 11/29/2006 07:00 EST http://www.prnewswire.com
